Search - tctmd.com

Displaying 81 - 100 of 133

Sort: Relevancy | Date

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

L.A. McKeown

October 16, 2018

News Daily News

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Michael O'Riordan

September 17, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Respiratory Syncytial Virus Linked With Cardiovascular Complications

Michael O'Riordan

April 04, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Daily News

Sixfold Higher Risk of Acute MI in the Week After Flu Diagnosis

Michael O'Riordan

January 24, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

Advertisement

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

Aspirin Falters Yet Again in Primary Prevention: ASPREE

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Respiratory Syncytial Virus Linked With Cardiovascular Complications

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Sixfold Higher Risk of Acute MI in the Week After Flu Diagnosis

TCTMD’s Top 10 Most Popular Stories for December 2017

New Performance and Quality Metrics for STEMI and NSTEMI Care

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content